摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Mercapto-phenyl)-cyclopropanecarboxylic acid methyl ester | 600134-93-8

中文名称
——
中文别名
——
英文名称
1-(4-Mercapto-phenyl)-cyclopropanecarboxylic acid methyl ester
英文别名
1-(4-mercaptophenyl)-1-cyclopropanecarboxylate methyl ester;Methyl 1-(4-mercaptophenyl)cyclopropane-1-carboxylate;methyl 1-(4-sulfanylphenyl)cyclopropane-1-carboxylate
1-(4-Mercapto-phenyl)-cyclopropanecarboxylic acid methyl ester化学式
CAS
600134-93-8
化学式
C11H12O2S
mdl
——
分子量
208.281
InChiKey
OFJUWRYDYQTHIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    299.1±33.0 °C(Predicted)
  • 密度:
    1.254±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    27.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds that modulate PPAR activity and methods of preparation
    申请人:——
    公开号:US20040209936A1
    公开(公告)日:2004-10-21
    This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    这项发明涉及改变PPAR活性的化合物。该发明还涉及这些化合物的药用盐、包含这些化合物或其盐的药用组合物,以及将它们用作治疗或预防哺乳动物中的脂质代谢异常、高胆固醇血症、肥胖、高血糖、动脉粥样硬化、高甘油三酯血症和高胰岛素血症的治疗剂的方法。本发明还涉及制备所述化合物的方法。
  • Compounds that modulate PPAR activity and methods for their preparation
    申请人:Auerbach Bruce J.
    公开号:US06875780B2
    公开(公告)日:2005-04-05
    This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    本发明涉及改变PPAR活性的化合物。本发明还涉及所述化合物的药学上可接受的盐、包含所述化合物或其盐的药学上可接受的组合物,以及将它们用作治疗或预防哺乳动物的脂质代谢紊乱、高胆固醇血症、肥胖症、高血糖症、动脉粥样硬化、高甘油三酯血症和高胰岛素血症的治疗剂的方法。本发明还涉及制备所述化合物的方法。
  • Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
    申请人:Fukui Yoshikazu
    公开号:US20070054902A1
    公开(公告)日:2007-03-08
    A compound of formula (I): (wherein R 1 -R 10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X 1 is —O—, —S—, —NR 11 — (wherein R 11 is hydrogen, lower alkyl or the like), —CR 12 R 13 CO—, —(CR 12 R 13 )mO—, —O(CR 12 R 13 )m- (wherein R 12 and R 13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X 2 is a bond, —O—, —S—, —NR 14 — (wherein R 14 is hydrogen, lower alkyl or the like, R 14 and R 6 can be taken together with the neighboring atom to form a ring) or —CR 15 R 16 — (wherein R 15 and R 16 are each independently hydrogen or lower alkyl, R 15 and R 6 or R 10 can be taken together with the neighboring carbon atom to form a ring, R 16 and R 9 can be joined together to form a bond), X 3 is COOR 17 , C(═NR 17 )NR 18 OR 19 or the like), a pharmaceutically acceptable salt or a solvate thereof.
    化合物的化学式为(I):(其中R1-R10各自独立地为氢,卤素,可选择性取代的低碳基或类似物,X1为—O—,—S—,—NR11—(其中R11为氢,低碳基或类似物),—CR12R13CO—,—(CR12R13)mO—,—O(CR12R13)m-(其中R12和R13各自独立地为氢或低碳基,m为1到3之间的整数)或类似物,X2为键,—O—,—S—,—NR14—(其中R14为氢,低碳基或类似物,R14和R6可以与相邻的原子结合形成环)或—CR15R16—(其中R15和R16各自独立地为氢或低碳基,R15和R6或R10可以与相邻的碳原子结合形成环,R16和R9可以结合在一起形成键),X3为COOR17,C(═NR17)NR18OR19或类似物),其药学上可接受的盐或溶剂化物。
  • ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
    申请人:SHIONOGI & CO., LTD.
    公开号:EP1690538A1
    公开(公告)日:2006-08-16
    A compound of formula (I) : (wherein R1-R10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X1 is -O-, -S-, -NR11- (wherein R11 is hydrogen, lower alkyl or the like), -CR12R13CO-, -(CR12R13)mO-, -O(CR12R13)m- (wherein R12 and R13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X2 is a bond, -O-, -S-, -NR14- (wherein R14 is hydrogen, lower alkyl or the like, R14 and R6 can be taken together with the neighboring atom to form a ring) or -CR15R16-(wherein R15 and R16 are each independently hydrogen or lower alkyl, R15 and R6 or R10 can be taken together with the neighboring carbon atom to form a ring, R16 and R9 can be joined together to form a bond), X3 is COOR17, C( = NR17)NR18OR19 or the like), a pharmaceutically acceptable salt or a solvate thereof.
    式 (I) 的化合物: 其中 R1-R10各自独立地为氢、卤素、任选取代的低级烷基或类似物,X1为-O-、-S-、-NR11-(其中R11为氢、低级烷基或类似物)、-CR12R13CO-、-(CR12R13)mO-、-O(CR12R13)m-(其中R12和R13各自独立地为氢或低级烷基,m为1至3之间的整数)或类似物、 X2 是键、-O-、-S-、-NR14-(其中 R14 是氢、低级烷基或类似物,R14 和 R6 可与邻近原子一起形成环)或-CR15R16-(其中 R15 和 R16 各自独立地是氢或低级烷基、R15和R6或R10可与邻近的碳原子结合形成环,R16和R9可结合形成键),X3为COOR17、C( = NR17)NR18OR19或类似物),其药学上可接受的盐或溶液。
  • THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY
    申请人:Warner-Lambert Company LLC
    公开号:EP1482935A1
    公开(公告)日:2004-12-08
查看更多